Animesh Pardanani

Summary

Affiliation: Mayo Clinic
Country: USA

Publications

  1. ncbi request reprint A role for tryptase in myeloid disorders?
    Animesh Pardanani
    Mayo Clinic, Division of Hematology, Rochester, MN 55905, USA
    Leuk Lymphoma 47:789-90. 2006
  2. ncbi request reprint Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease
    Animesh Pardanani
    Mayo Clinic, Rochester, MN 55905, USA
    Cancer J 13:384-91. 2007
  3. doi request reprint Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine
    Ken H Lim
    Divisions of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 84:790-4. 2009
  4. ncbi request reprint FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Laboratory Geentics and Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:3038-45. 2004
  5. doi request reprint Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 84:518-24. 2010
  6. ncbi request reprint Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 88:201-6. 2013
  7. ncbi request reprint Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates
    Naseema Gangat
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 80:197-200. 2008
  8. doi request reprint Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Am J Hematol 85:238-42. 2010
  9. doi request reprint DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status
    Naseema Gangat
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 29:392-7. 2011
  10. pmc Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 85:158-64. 2010

Detail Information

Publications98

  1. ncbi request reprint A role for tryptase in myeloid disorders?
    Animesh Pardanani
    Mayo Clinic, Division of Hematology, Rochester, MN 55905, USA
    Leuk Lymphoma 47:789-90. 2006
  2. ncbi request reprint Hypereosinophilic syndrome, chronic eosinophilic leukemia, and mast cell disease
    Animesh Pardanani
    Mayo Clinic, Rochester, MN 55905, USA
    Cancer J 13:384-91. 2007
    ..In addition, a number of new drugs are currently being tested for their safety and efficacy in all 3 disorders...
  3. doi request reprint Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine
    Ken H Lim
    Divisions of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 84:790-4. 2009
    ....
  4. ncbi request reprint FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Laboratory Geentics and Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Blood 104:3038-45. 2004
    ..In contrast, only 40% partial response rate was seen in 10 HES cases. FIP1L1-PDGFRA is a relatively infrequent but treatment-relevant mutation in primary eosinophilia that is indicative of an underlying systemic mastocytosis...
  5. doi request reprint Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 84:518-24. 2010
    ..The current study was designed to provide additional data in this regard...
  6. ncbi request reprint Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: prevalence, clinical correlates, and prognostic relevance
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 88:201-6. 2013
    ..We conclude that SRSF2 is the most frequently mutated spliceosome gene in CMML but neither it nor SF3B1 or U2AF35 mutations are prognostically relevant...
  7. ncbi request reprint Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates
    Naseema Gangat
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 80:197-200. 2008
    ..02), but not JAK2V617F allele burden, thrombosis, hemorrhage, leukemic/fibrotic transformation, or survival. We conclude that cytogenetic anomalies occur infrequently at PV diagnosis and do not confer an adverse outcome...
  8. doi request reprint Chromosome 8p11.2 translocations: prevalence, FISH analysis for FGFR1 and MYST3, and clinicopathologic correlates in a consecutive cohort of 13 cases from a single institution
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, Rochester, MN, USA
    Am J Hematol 85:238-42. 2010
    ..We conclude that neither the SCLL phenotype nor blood eosinophilia is a consistent feature of FGFR1-associated 8p11.2 translocations; conversely, FISH might not always reveal FGFR1 involvement in typical SCLL...
  9. doi request reprint DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status
    Naseema Gangat
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 29:392-7. 2011
    ..The main objective of this study was to refine DIPSS by incorporating prognostic information from karyotype, platelet count, and transfusion status...
  10. pmc Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 85:158-64. 2010
    ..In the current review, we provide a simplified algorithm for distinguishing the various causes of clonal and idiopathic eosinophilia and discuss current therapy, including new drugs (imatinib mesylate, alemtuzumab, and mepolizumab)...
  11. doi request reprint The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea
    Shireen Sirhan
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Am J Hematol 83:363-5. 2008
    ..02). The current study suggests that JAK2V617F presence identifies PMF patients who are likely to respond to HU therapy, and information on its allele burden helps in assigning the optimal starting dose in individual patients with PV...
  12. pmc One thousand patients with primary myelofibrosis: the mayo clinic experience
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 87:25-33. 2012
    ..To share our decades of experience with primary myelofibrosis and underscore the importance of outcomes research studies in designing clinical trials and interpreting their results...
  13. doi request reprint Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis
    Rakhee Vaidya
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 87:1003-5. 2012
    ..03) maintained their association with shortened survival, on multivariable analysis. This study provides preliminary observations that warrant a larger scale study and suggests the value of plasma cytokines as prognostic biomarkers in PV...
  14. doi request reprint SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 119:569-72. 2012
    ..In other words, when RARS and RCMD-RS were analyzed separately, there was no additional prognostic value from the presence or absence of SF3B1 mutations...
  15. ncbi request reprint Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA
    Stem Cells 25:2358-62. 2007
    ..These observations suggest that clonal myelopoiesis antedates acquisition of JAK2V617F or MPLW515L/K mutations and that the latter is acquired in a lympho-myeloid progenitor cell...
  16. doi request reprint 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 80:386-90. 2008
    ....
  17. doi request reprint SRSF2 mutations in primary myelofibrosis: significant clustering with IDH mutations and independent association with inferior overall and leukemia-free survival
    Terra L Lasho
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 120:4168-71. 2012
    ..01; HR = 1.9; 95% CI, 1.1-3.0) and IDH mutations (P < .01; HR = 2.3; 95% CI, 1.4-3.8). In conclusion, SRSF2 mutations are relatively common in PMF, cluster with IDH mutations, and are independently predictive of poor outcome...
  18. doi request reprint Polyclonal immunoglobulin free light chain levels predict survival in myeloid neoplasms
    Animesh Pardanani
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 30:1087-94. 2012
    ..Because of immediate practical applicability, we chose plasma immunoglobulin free light chain (FLC) concentration as the biomarker of interest...
  19. doi request reprint Predictors of greater than 80% 2-year mortality in primary myelofibrosis: a Mayo Clinic study of 884 karyotypically annotated patients
    Ayalew Tefferi
    Divisions of Hematology, Mayo Clinic, Rochester, MN, USA
    Blood 118:4595-8. 2011
    ..2, 95% confidence interval 1.6-3.1; P < .01). The present information complements DIPSS-plus in the selection of primary myelofibrosis patients for high-risk treatment approaches...
  20. doi request reprint Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 114:3769-72. 2009
    ....
  21. pmc Mature survival data for 176 patients younger than 60 years with primary myelofibrosis diagnosed between 1976 and 2005: evidence for survival gains in recent years
    Rakhee Vaidya
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 84:1114-9. 2009
    ..002), not in those with low-risk disease (P=.42). These observations are encouraging and suggest a salutary effect from modern therapeutic approaches in PMF...
  22. doi request reprint Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
    Ayalew Tefferi
    Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 122:1395-8. 2013
    ..Additional criteria are provided for progressive disease, stable disease, and relapse. The document also includes recommendations for assessing cytogenetic and molecular remissions, without mandating their inclusion for CR assignment. ..
  23. doi request reprint Systemic mastocytosis in adults: 2011 update on diagnosis, risk stratification, and management
    Animesh Pardanani
    Department of Medicine, Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 86:362-71. 2011
    ..Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MC) in one or more extracutaneous organs...
  24. ncbi request reprint Eosinophilia: secondary, clonal and idiopathic
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Br J Haematol 133:468-92. 2006
    ..The current communication features a comprehensive clinical summary of both secondary and primary eosinophilic disorders with emphasis on recent developments in molecular pathogenesis and treatment...
  25. doi request reprint Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Hematol 88:312-6. 2013
    ..4; P = 0.002), and could be considered in future prognostic models for PMF...
  26. doi request reprint Systemic mastocytosis in adults: 2012 Update on diagnosis, risk stratification, and management
    Animesh Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 87:401-11. 2012
    ..Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MC) in one or more extra-cutaneous organs...
  27. doi request reprint Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors
    Ken Hong Lim
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Blood 113:5727-36. 2009
    ..The current study validates the prognostic relevance of the WHO subclassification of SM and provides additional information of value in terms of both risk stratification and interpretation of clinical presentation and laboratory results...
  28. doi request reprint Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: clinical correlates and prognostic studies
    Animesh Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Am J Hematol 86:1013-6. 2011
    ..05). We conclude that while hypovitaminosis D is relatively common in MPN and MDS, its clinical relevance for prognosis is limited...
  29. doi request reprint Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study
    Ayalew Tefferi
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 29:1356-63. 2011
    ..This study describes the spectrum of plasma cytokine abnormalities in primary myelofibrosis (PMF) and examines their phenotypic correlates and prognostic significance...
  30. ncbi request reprint Clinical, genetic, and therapeutic insights into systemic mast cell disease
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Curr Opin Hematol 11:58-64. 2004
    ..The purpose of this review is to summarize current concepts and recent advances in the pathogenesis and treatment of adult mast cell disease...
  31. doi request reprint TP53 mutations and polymorphisms in primary myelofibrosis
    Sania Raza
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Am J Hematol 87:204-6. 2012
    ..There were no significant differences among the three codon 72 genotypes in terms of presenting characteristics or survival...
  32. doi request reprint Sole abnormalities of chromosome 7 in myeloid malignancies: spectrum, histopathologic correlates, and prognostic implications
    Fareeda Taher Nazer Hussain
    Mayo Medical School, Mayo Clinic and Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Am J Hematol 87:684-6. 2012
    ..57 and 0.81, respectively). The current study does not prognostically distinguish monosomy 7 from 7q- or der(1;7), in MDS...
  33. doi request reprint Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy
    Michelle A Elliott
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 88:237-43. 2012
    ..Therapy-related APL is sensitive to standard therapy with no cases of resistance or relapse seen. The inferior OS of the t-APL was due to induction mortality, possibly reflecting prior therapy...
  34. ncbi request reprint Clinical correlates of JAK2V617F allele burden in essential thrombocythemia
    Jaya Kittur
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:2279-84. 2007
    ..A possible association with thrombotic complication has also been considered...
  35. doi request reprint Monosomal karyotype in primary myelofibrosis is detrimental to both overall and leukemia-free survival
    Rakhee Vaidya
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA
    Blood 117:5612-5. 2011
    ..8 (1.7-130.8). The prognostic relevance of MK was not accounted for by the Dynamic International Prognostic Scoring System. We conclude that MK in primary myelofibrosis is associated with extremely poor overall and leukemia-free survival...
  36. ncbi request reprint Karyotype complements the International Prognostic Scoring System for primary myelofibrosis
    Kebede Hussein
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Eur J Haematol 82:255-9. 2009
    ..The presence of 0, 1, 2, and > or =3 adverse factors defines low, intermediate-1, intermediate-2, and high risk disease, respectively. We examined the additional prognostic relevance of karyotype...
  37. doi request reprint Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:14-7. 2010
    ..We conclude that transfusion status in PMF downgrades or upgrades prognosis within specific IPSS categories; transfusion need is a marker of aggressive disease biology in PMF, as it is in myelodysplastic syndromes...
  38. ncbi request reprint Imatinib therapy for hypereosinophilic syndrome and eosinophilia-associated myeloproliferative disorders
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 28:S47-52. 2004
    ..These observations make it necessary to re-examine current disease classification and treatment algorithms in eosinophilic disorders...
  39. doi request reprint JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    Mayo Clin Proc 83:457-9. 2008
    ..Our study also suggests that the natural history of a JAK2V617F-positive "occult" MPN might be different from that of a typical MPN...
  40. doi request reprint Systemic mastocytosis in adults: 2013 update on diagnosis, risk stratification, and management
    Animesh Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota
    Am J Hematol 88:612-24. 2013
    ..Systemic mastocytosis (SM) results from a clonal proliferation of abnormal mast cells (MC) in one or more extracutaneous organs...
  41. doi request reprint Pruritus in polycythemia vera is associated with a lower risk of arterial thrombosis
    Naseema Gangat
    Division of Hematology, Department of Medicine and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota55905, USA
    Am J Hematol 83:451-3. 2008
    ..30%; P = 0.003). Multivariable analysis revealed that these associations were independent of other risk factors for thrombosis. High JAK2V617F allele burden clustered with pruritus (P = 0.002) but did not affect thrombosis rates...
  42. ncbi request reprint Risk factors for leukemic transformation in patients with primary myelofibrosis
    Jocelin Huang
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 112:2726-32. 2008
    ..However, to the authors' knowledge, information regarding risk factors for leukemic transformation in primary myelofibrosis is limited...
  43. doi request reprint Pruritus in primary myelofibrosis: clinical and laboratory correlates
    Brianna E Vaa
    Mayo Medical School, Rochester, MN 55905, USA
    Am J Hematol 87:136-8. 2012
    ..The apparently differential effect of MPL vs. JAK2 mutations on pruritus requires further investigation...
  44. doi request reprint Comparison of complication rates of Hickman(®) catheters versus peripherally inserted central catheters in patients with acute myeloid leukemia undergoing induction chemotherapy
    Ming Y Lim
    Department of Internal Medicine, Mayo Clinic Rochester, Rochester, MN, USA
    Leuk Lymphoma 54:1263-7. 2013
    ..The choice of type of CVAD inserted into patients with newly diagnosed AML will depend on ease of catheter placement, cost, perception of frequency and severity of complications, and clinician preference...
  45. doi request reprint Targeting myeloproliferative neoplasms with JAK inhibitors
    Animesh Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Curr Opin Hematol 18:105-10. 2011
    ..Here, we review the current experience with JAK inhibitors used for the treatment of myelofibrosis and polycythemia vera/essential thrombocythemia...
  46. doi request reprint Long-term outcome of pomalidomide therapy in myelofibrosis
    Kebede H Begna
    Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Am J Hematol 87:66-8. 2012
    ..19). Long-term follow-up of pomalidomide treatment in MF reveals palliative value for a select group of patients and treatment-emergent sensory neuropathy...
  47. doi request reprint KIT and mastocytosis
    Ken Hong Lim
    Division of Hematology, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Acta Haematol 119:194-8. 2008
    ..In general, conventional therapy for SM is suboptimal, and efforts are under way to develop and employ small molecule drugs that target mutant KIT...
  48. doi request reprint Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 29:789-96. 2011
    ..Patients frequently harbor JAK-STAT activating mutations that are sensitive to TG101348, a selective small-molecule Janus kinase 2 (JAK2) inhibitor...
  49. doi request reprint Age and platelet count are IPSS-independent prognostic factors in young patients with primary myelofibrosis and complement IPSS in predicting very long or very short survival
    Mrinal M Patnaik
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Eur J Haematol 84:105-8. 2010
    ..The study also examined the overall risk profile of long-term (>15 yr) and short-term (<5 yr) survivors...
  50. ncbi request reprint Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 111:2785-9. 2008
    ..Thus, host genetic variation may contribute to phenotypic diversity among myeloproliferative disorders, including in the presence of a shared disease allele...
  51. ncbi request reprint Imatinib therapy in clonal eosinophilic disorders, including systemic mastocytosis
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Int J Hematol 79:441-7. 2004
    ..The bone marrow histologic phenotype of these imatinib-sensitive eosinophilic disorders includes systemic mastocytosis, chronic eosinophilic leukemia, chronic myelomonocytic leukemia, and atypical chronic myeloproliferative disorder...
  52. doi request reprint Red blood cell transfusion need at diagnosis adversely affects survival in primary myelofibrosis-increased serum ferritin or transfusion load does not
    Ayalew Tefferi
    Division of Hematology Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 84:265-7. 2009
    ..003). In PMF, the presence of a more severe erythropoietic defect, and not iron overload, has additional adverse prognostic value...
  53. ncbi request reprint Dysregulated EVI1 expression in myeloid malignancies
    Animesh Pardanani
    Mayo Clinic, Division of Hematology, Rochester, MN 55905, USA
    Leuk Lymphoma 47:2443-4. 2006
  54. doi request reprint Oligonucleotide array CGH studies in myeloproliferative neoplasms: comparison with JAK2V617F mutational status and conventional chromosome analysis
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN, USA
    Leuk Res 33:662-4. 2009
    ..This preliminary report suggests a potential value for array CGH in terms of both clinical diagnostics and genomic research in MPNs...
  55. ncbi request reprint Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation
    Naseema Gangat
    Division of Hematology, Department of Medicine, Laboratory Medicine, and Health Sciences Research, Mayo Clinic, Rochester, MN, USA
    Br J Haematol 138:354-8. 2007
    ..The current study highlighted the prognostic relevance of leucocytosis on various aspects of the disease in PV...
  56. doi request reprint Circulating levels of MCP-1, sIL-2R, IL-15, and IL-8 predict anemia response to pomalidomide therapy in myelofibrosis
    Animesh Pardanani
    Division of Hematology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 86:343-5. 2011
    ..Current data suggest that, in the context of pomalidomide treatment, response is more likely in the presence of JAK2V617F and further predicted by the absence of marked splenomegaly or increased levels of proinflammatory cytokines...
  57. pmc Thrombosis in myelofibrosis: prior thrombosis is the only predictive factor and most venous events are provoked
    Michelle Ann Elliott
    Division of Hematology Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 95:1788-91. 2010
    ..007) and venous (P=0.02) thromboses were analyzed separately. The current study demonstrates a higher prevalence of venous, as opposed to arterial, events in PMF, post-diagnosis, and clarifies their nature as being mostly provoked...
  58. doi request reprint Bone marrow morphologic features in polycythemia vera with JAK2 exon 12 mutations
    Meredith A Lakey
    Division of Hematopathology Mayo Clinic College of Medicine, 200 1st Street SW, Rochester, MN 55905, USA
    Am J Clin Pathol 133:942-8. 2010
    ..Clinically suspected PV with low serum erythropoietin and absent JAK2(V617F), together with the bone marrow findings of erythroid hyperplasia and subtle megakaryocytic atypia, should prompt an evaluation for an exon 12 mutation...
  59. ncbi request reprint Validation and comparison of contemporary prognostic models in primary myelofibrosis: analysis based on 334 patients from a single institution
    Ayalew Tefferi
    Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 109:2083-8. 2007
    ..Two other PSSs, Cervantes and Mayo, were recently reported as being more useful in younger patients. The current study compares these 3 PSSs among all age groups...
  60. pmc Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 86:1188-91. 2011
    ....
  61. ncbi request reprint Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 27:883-5. 2003
    ..The clinical implications of this finding are discussed...
  62. ncbi request reprint Imatinib targets other than bcr/abl and their clinical relevance in myeloid disorders
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Blood 104:1931-9. 2004
    ..Imatinib is considered investigational for the treatment of hematologic malignancies without a defined molecular drug target, such as polycythemia vera, myelofibrosis with myeloid metaplasia, and acute myeloid leukemia...
  63. ncbi request reprint Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time
    Terra L Lasho
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 135:683-7. 2006
    ..We conclude that MPLW515L/K and JAK2V617F are both early events in MMM and allele burden, rather than the mere presence of these mutations, might be relevant to phenotypic variation in myeloproliferative disorders...
  64. ncbi request reprint MPL W515 and JAK2 V617 mutation analysis in patients with refractory anemia with ringed sideroblasts and an elevated platelet count
    David P Steensma
    Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Haematologica 91:ECR57. 2006
    ....
  65. ncbi request reprint Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:3391-7. 2003
    ..Myocardial biopsy revealed eosinophilic infiltration and degranulation, and the cardiogenic shock was reversed with the prompt institution of corticosteroid therapy...
  66. ncbi request reprint Mutation screening for JAK2V617F: when to order the test and how to interpret the results
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 30:739-44. 2006
    ..Therefore, mutation screening for JAK2V617F can be considered as a myeloid-specific clonality assay and it is diagnostically most useful in the evaluation of "polycythemia"...
  67. doi request reprint Neurologic symptoms and diagnosis in adults with mast cell disease
    Jonathan H Smith
    Department of Neurology, Mayo Clinic, 200 Second Street, Rochester, MN 55905, United States
    Clin Neurol Neurosurg 113:570-4. 2011
    ..To identify complications of mastocytosis that impact the nervous system across a large cohort...
  68. pmc TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells
    Vijay Ramakrishnan
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Am J Hematol 85:675-86. 2010
    ..Our results provide the rationale for clinical evaluation of TG101209 alone or in combination with PI3K/Akt inhibitors in MM...
  69. ncbi request reprint Evaluation of "increased" hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests
    Ayalew Tefferi
    Division of Hematology, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Mayo Clin Proc 82:599-604. 2007
    ....
  70. doi request reprint Primary eosinophilic disorders: a concise review
    Animesh Pardanani
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Curr Hematol Malig Rep 3:37-43. 2008
    ....
  71. doi request reprint Systemic mastocytosis in adults: a review on prognosis and treatment based on 342 Mayo Clinic patients and current literature
    Animesh Pardanani
    Department of Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Curr Opin Hematol 17:125-32. 2010
    ..The current review provides an update on prognosis and treatment of systemic mastocytosis, including investigational drug therapy...
  72. ncbi request reprint Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease
    Jin Young Baek
    Division of Hematopathology and Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 26:83-90. 2002
    ..The results confirm the diagnostic value of Kit immunohistochemistry in MCD and suggest a biologically relevant heterogeneity in TGFbeta1R expression among patients with SMCD-HD...
  73. ncbi request reprint Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 99:3854-6. 2002
    ..In vitro, imatinib mesylate caused variable degrees of growth suppression of myeloid and erythroid progenitors that unfortunately did not translate into clinical benefit...
  74. ncbi request reprint Atypical myeloproliferative disorders: diagnosis and management
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Mayo Clin Proc 81:553-63. 2006
    ....
  75. ncbi request reprint Treatment of hypereosinophilic syndrome with imatinib mesilate
    Gerald J Gleich
    Department of Immunology, Allergic Diseases Research Laboratory, Mayo Clinic and Foundation, Rochester, MN, USA
    Lancet 359:1577-8. 2002
    ..All patients who responded stopped other treatments and reduced imatinib mesilate to 200 mg per week. This drug effectively controls eosinophilia in patients with hypereosinophilic syndrome and normal interleukin-5 concentrations...
  76. ncbi request reprint Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:827-30. 2003
    ..008). The prognostic value of circulating PBPCs may help select treatment for patients with AL...
  77. ncbi request reprint Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:1169-75. 2002
    ..To study clinicopathologic correlations and identify prognostically important variables in patients with systemic mast cell disease (SMCD) who have no associated hematologic disorders...
  78. ncbi request reprint Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder
    Animesh Pardanani
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 120:691-4. 2003
    ..04). Furthermore, no correlation was found between mast cell CD2 expression and other clinicopathological features in these patients...
  79. ncbi request reprint Systemic mastocytosis: current concepts and treatment advances
    Ayalew Tefferi
    Division of Hematology, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55902, USA
    Curr Hematol Rep 3:197-202. 2004
    ..Cladribine has been shown to be effective in patients who develop resistance to interferon treatment...
  80. ncbi request reprint CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Blood 102:3093-6. 2003
    ..Screening for the FIP1L1-PDGFRA rearrangement and Asp816Val mutation will advance rational therapy decisions in SMCD...
  81. ncbi request reprint Bone marrow angiogenesis in systemic mast cell disease
    Jin Young Baek
    Divisions of Hematopathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Hematother Stem Cell Res 11:139-46. 2002
    ..We conclude that bone marrow angiogenesis characterizes a percentage of patients with SMCD and that the pathogenesis may not necessarily be linked to the mast cells themselves...
  82. ncbi request reprint Long-term outcome of treatment with ruxolitinib in myelofibrosis
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN
    N Engl J Med 365:1455-7. 2011
    ..The control of splenomegaly may not be durable, and the likelihood of leukemic progression or death is not dramatically lowered...
  83. pmc Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients
    Carrie A Thompson
    Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Am J Hematol 85:171-3. 2010
    ..Optimal management of AL patients with FX deficiency undergoing invasive procedures remains to be determined...
  84. pmc Malignant melanoma in the 21st century: the emerging molecular landscape
    Aleksandar Sekulic
    Department of Dermatology, Mayo Clinic, Scottsdale, AZ 85259, USA
    Mayo Clin Proc 83:825-46. 2008
    ..We review the emerging molecular landscape of melanoma and its implications for better management of patients with melanoma...
  85. ncbi request reprint Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Leuk Res 27:739-42. 2003
    ..In SMCD, the presence of D816V mutation was significantly associated with advanced age, an aggressive clinical course, increased bone marrow mast cell content, and chronic myelomonocytic leukemia...
  86. ncbi request reprint 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, 200 First St SW, Rochester, Minn 55905, USA
    Mayo Clin Proc 78:301-6. 2003
    ..To evaluate the efficacy of 2-chlorodeoxyadenosine (2-CDA), a purine nucleoside analogue, in treating disseminated Langerhans cell histiocytosis (LCH)...
  87. ncbi request reprint A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia
    Ruben A Mesa
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Blood 101:2534-41. 2003
    ..Clinical responses did not correlate with improvements in either intramedullary fibrosis or angiogenesis. THAL-PRED is well tolerated and preliminarily appears to be a promising drug regimen for treating cytopenias in patients with MMM...
  88. ncbi request reprint Hypereosinophilic syndrome with elevated serum tryptase versus systemic mast cell disease associated with eosinophilia: 2 distinct entities?
    Ayalew Tefferi
    Blood 102:3073-4; author reply 3074. 2003
  89. ncbi request reprint FIP1L1-PDGFRA and c-kit D816V mutation-based clonality studies in systemic mast cell disease associated with eosinophilia
    Ayalew Tefferi
    Haematologica 89:871-3. 2004
    ..The results suggested an early stem cell origin for the FIP1L1-PDGFRA mutation...
  90. ncbi request reprint Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis
    Srdan Verstovsek
    Leukemia Department, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:3906-15. 2008
    ....
  91. pmc Methylation of RUNX1 by PRMT1 abrogates SIN3A binding and potentiates its transcriptional activity
    Xinyang Zhao
    Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Genes Dev 22:640-53. 2008
    ..These arginine methylation sites and the dynamic regulation of corepressor binding are lost in the leukemia-associated RUNX1-ETO fusion protein, which likely contributes to its dominant inhibitory activity...
  92. ncbi request reprint Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders
    Animesh Pardanani
    Blood 107:4572-3. 2006
  93. doi request reprint How we diagnose and treat WHO-defined systemic mastocytosis in adults
    Ayalew Tefferi
    Haematologica 93:6-9. 2008
  94. ncbi request reprint Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
    Ross L Levine
    Brigham and Women s Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02155, USA
    Nat Rev Cancer 7:673-83. 2007
    ....
  95. ncbi request reprint Primer on medical genomics. Part IV: Expression proteomics
    Animesh Pardanani
    Division of Hematology and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA
    Mayo Clin Proc 77:1185-96. 2002
    ..This task has been made considerably easier with the availability of complete, nonredundant, and annotated genome sequence databases for many organisms. This article reviews the area of expression proteomics...
  96. ncbi request reprint Systemic mastocytosis: a concise clinical and laboratory review
    Mrinal M Patnaik
    Department of Medicine, University of Minnesota, Minneapolis, USA
    Arch Pathol Lab Med 131:784-91. 2007
    ..The clinical presentation is varied and may include skin rash, symptoms related to release of mast cell mediators, and/or organopathy from involvement of bone, liver, spleen, bowel, or bone marrow...
  97. pmc More on Myb in myelofibrosis: molecular analyses of MYB and EP300 in 55 patients with myeloproliferative disorders
    David P Steensma
    Blood 107:1733-5; author reply 1735. 2006
  98. ncbi request reprint Kit: molecule of interest for the diagnosis and treatment of mastocytosis and other neoplastic disorders
    Mrinal M Patnaik
    Department of Internal Medicine, University of Minnesota, Minneapolis, MN 55455, USA
    Curr Cancer Drug Targets 7:492-503. 2007
    ....